Navigation Links
As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
Date:2/23/2009

Percentage of Clinicians Performing hsCRP Testing Will Increase Dramatically Over the Next Six Months, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, as a result of the JUPITER clinical trial, 65 percent of surveyed managed care organizations' (MCO) pharmacy directors say they will reimburse AstraZeneca's Crestor for healthy patients with elevated levels of high sensitivity C-reactive protein (hsCRP). The JUPITER trial enrolled apparently healthy subjects without high LDL cholesterol but with elevated hsCRP and randomized subjects to receive Crestor or placebo. Trial data showed a 44 percent reduction in major cardiovascular events and reduced all-cause mortality by 20 percent among participants receiving Crestor.

The new Physician & Payer Forum report entitled The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? finds that 15 percent of surveyed MCO pharmacy directors will grant Crestor more favorable tier status in light of the trial. Crestor is currently on tier one of only 10 percent of surveyed MCO private health plans, while Pfizer's Lipitor is on tier one of 30 percent of surveyed MCO plans. Additionally, among Medicare prescription drug plans, Crestor has the highest rate of coverage among branded statins.

"Our findings suggest that in response to the JUPITER trial data, many clinicians will start using a statin ahead of diet and exercise changes," said Decision Resources Analyst Graeme Green, Ph.D. "Most of these clinicians will favor Crestor for these patients, indicating that AstraZeneca will benefit the most from such a trend."

The report finds that, in response to JUPITER trial data, the percentage of clinicians performing hsCRP testing will increase dramatically over the next six months among patients with and without cardiovascular risk factors. Surveyed clinicians anticipate that the percentage of patients with no cardiovascular risk factors tested for elevated hsCRP will increase from 5 percent in July 2008, to 26 percent in July 2009. The percentage of patients with two or more cardiovascular risk factors tested by primary care physicians for hsCRP will increase from 16 percent in July 2008 to 40 percent in July 2009.

The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? is based on a U.S. survey of 71 primary care physicians, 72 cardiologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                           Decision Resources, Inc.
    Christopher Comfort                          Elizabeth Marshall
    781-296-2597                                 781-296-2563
    ccomfort@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
2. XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
3. Insulet Corporation to Report Fourth Quarter and Full Year 2008 Financial Results on Thursday, March 5, 2009
4. WebMD Announces Fourth Quarter Financial Results
5. Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
6. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
7. HLTH Corporation Announces Fourth Quarter Financial Results
8. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
9. Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Fourth Quarter 2008 Earnings Results Webcast
10. QLT Announces Fourth Quarter and Year End 2008 Results
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... Ga. (PRWEB) , ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook ... examine our budgets and look for ways to trim the fat from our monthly expenses ... your finances, but it’s also important that you have a financial safety net in place ...
(Date:8/31/2020)... PASADENA, Calif. (PRWEB) , ... August 31, 2020 ... ... and leadership experience working, both directly with persons with autism and other developmental ... clinical expertise includes early intervention, parent education, adolescents with autism, school consultation, and ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ernst & ... was named an Entrepreneur Of The Year® 2020 Florida Award finalist. Now in ... whose ambitions deliver innovation, growth and prosperity as they build and sustain successful ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person gluten-free events ... continue helping the specialty-diet community connect with great, gluten-free brands. At the ... giveaways, chat with brands & watch over 50 educational classes... all online from ...
(Date:8/28/2020)... ... August 28, 2020 , ... A ... suggest that obese individuals are at an increased risk of developing severe COVID-19 ... to catch COVID-19; however, because the same organ systems that the coronavirus attacks ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... ... August 31, 2020 , ... Continuing on ... a broad-spectrum sanitization, disinfection and deodorization provider - is proud to announce it ... disinfecting services for businesses and residents throughout the area. , Germinator provides a ...
(Date:8/28/2020)... ... August 28, 2020 , ... Dr. Raheleh ... a unique perspective and approach. Armed with her qualifications from Ross University School ... her knowledge of the human body with the nation and world. With a ...
(Date:8/27/2020)... ... August 27, 2020 , ... Bleep LLC, maker of the DreamPort mask-less ... is the company’s new spokesperson. , “In my line of work, a good night ... the Bleep DreamPort it was a Bleeping no brainer for me,” said Jensen. “From ...
Breaking Medicine Technology: